Works in mice? It’s a winner for Homology as IPO reaps $144M haul, with biotech on a roll
Gene editing remains one of the hottest games in biopharma, well before we get to see any human data from clinical trials.
Tuesday evening Bedford, MA-based Homology Medicines came up with a $144 million catch, pricing a seriously upsized offering of 9 million shares at $16 a pop, the high end of the range.
Shares will start trading tomorrow under the $FIXX symbol.
Homology’s claim to fame is its new gene editing tech, steering around CRISPR in favor of using viral vectors to deliver snippets of DNA where needed. As of now that’s only been done in mice, but they signed Novartis as a partner and it was all good enough for the biotech’s backers. Homology had initially pencilled in $100 million for the goal, but a slate of IPOs in Q1 has delivered some hefty premiums well past their initial estimates.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
